Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
78
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Hodgkin Lymphoma
Advanced Solid Tumor
Interventions
DRUG:
AXT-1003
Sponsor
Axter Therapeutics (Beijing) Co., Ltd